Smith 2005.

Study characteristics
Methods	Multicentre, R, DB, DD, parallel group. Single dose to treat single attack Medication taken when pain ≥ moderate Assessments at 0, 15 min intervals to 2 h, 30 min to 4 h, hourly to 24 h
Participants	Migraine ± aura (IHS 2004), aged ≥ 18 years. History ≥ 1 year with 2 to 6 attacks per month, and able to tolerate oral triptan or ergot derivative N = 972 F = 91% Mean age 42 years Without aura: > 70%
Interventions	Sumatriptan 50 mg plus naproxen 500 mg, n = 251 Sumatriptan 50 mg, n = 229 Naproxen 500 mg, n = 250 Placebo, n = 242 Rescue medication allowed after 2 h if necessary (not specified)
Outcomes	Headache relief at 1 and 2 h Pain‐free at 2 h 24‐h sustained headache relief 24‐h sustained pain‐free Presence and relief of functional disability at 2 h Presence and relief of associated symptoms at 2 h Use of rescue medication AEs Withdrawals
Notes	Oxford Quality Score: R1, DB2, W1. Total = 4
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding (performance bias and detection bias) All outcomes	Low risk	DD method, with sumatriptan encapsulated
Incomplete outcome data (attrition bias) All outcomes	Low risk	Drop‐outs described
Study size	Low risk	> 200 participants per treatment arm